Debiopharm taps Singapore expertise for epigenetic drug discovery deal
This article was originally published in Scrip
Executive Summary
Debiopharm has entered into a basic research collaboration with the Experimental Therapeutics Centre (ETC) of Singapore's Agency for Science, Technology and Research (A*STAR), to develop oral small molecule modulators of epigenetic function.